Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
FDA delay
Biotech
FDA delays decision on Ascendis' dwarfism prospect by 3 months
The FDA pushed back the decision deadline by three months to buy time to review recently submitted information.
Nick Paul Taylor
Nov 26, 2025 9:45am
Denali's Hunter syndrome drug latest to be hit by FDA delay
Oct 14, 2025 8:09am
After delay, Coya receives FDA go-ahead for phase 2 ALS trial
Aug 25, 2025 11:04am
Regenxbio's Hunter gene therapy latest to face FDA delay
Aug 19, 2025 10:30am
Another biotech hit with FDA delay for ALS asset
Aug 18, 2025 11:01am
FDA delays decision on Biohaven troriluzole filing, plans adcomm
May 15, 2025 6:02am
